ClinicalTrials.gg
CompletedNCT01868061Updated May 19, 2017

A Study of Lebrikizumab in Participants With Uncontrolled Asthma on Inhaled Corticosteroids and a Second Controller Medication

A Phase 3 interventional study of Lebrikizumab and Placebo in Asthma, sponsored by Hoffmann-La Roche. Completed at 232 sites in 26 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-05-19.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,068
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing lebrikizumab in Asthma — none open to participants now, none under way, none of them phase 3. lebrikizumab · Asthma.

Enrollment
2nd of 12
1,068 · median 224
Started
2013
with 2 others
Phase 3
5 of 12
none open now
Registered
7th of 12
by date
Lead sponsor
7 of 12
Hoffmann-La Roche

Among the 12 studies testing lebrikizumab in Asthma, this one is the 2nd largest by enrollment, is one of 3 that started in 2013, is one of 5 in phase 3, and was the 7th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 12 studies testing lebrikizumab in Asthma is open now. The open studies under Asthma, anywhere →

About lebrikizumab

lebrikizumab: first FDA approval 2024 (EBGLYSS), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing lebrikizumab in Asthma as a file.
02

Study summary

This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of lebrikizumab in participants with asthma whose disease remains uncontrolled despite daily treatment with inhaled corticosteroid (ICS) therapy and at least one second controller medication. Participants will be randomized in 1:1:1 ratio to receive double-blind treatment with either lebrikizumab ("high" or "low") or placebo, administered as subcutaneous (SC) injection every 4 weeks for 52 weeks, in addition to their standard-of-care therapy. This will be followed by a 52-week double-blind active treatment extension. Participants who were assigned to placebo during the placebo-controlled period of the trial will be re-randomized at Week 52 to receive blinded SC lebrikizumab 37.5 milligrams (mg) or 125 mg every 4 weeks from Weeks 53 to 104. The anticipated time on study treatment is 104 weeks. After study treatment, all participants will complete a 20-week safety follow-up.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Asthma diagnosis for greater than equal to (>/=) 12 months at Visit 1
  • Bronchodilator response at Visit 1, 2, or 3
  • Pre-bronchodilator of 40 percent (%) - 80% predicted at both Visits 2 and 3
  • On ICS therapy at a total daily dose of 500-2000 microgram (mcg) of fluticasone propionate dry powder inhaler (DPI) or equivalent for >/= 6 months prior to Visit 1
  • On an eligible second controller medication (long-acting Beta-agonist [LABA], leukotriene receptor antagonist [LTRA], long-acting muscarinic antagonist [LAMA], or theophylline) for 6 months prior to Visit 1
  • Uncontrolled asthma at Visit 1 and/or Visit 2, and at Visit 3
  • Chest X-ray or computed tomography (CT) scan within 3 months prior to Visit 1 or chest X-ray during the screening period (prior to Visit 3) confirming the absence of other lung disease
  • Demonstrated adherence with controller medication during the screening period

Exclusion criteria

Exclusion Criteria:

  • History of severe allergic reaction or anaphylactic reaction to a biologic agent or known to any component of the lebrikizumab injection
  • Maintenance oral therapy within 3 months of Visit 1
  • Treatment with systemic (oral, intravenous [IV], or intramuscular [IM]) corticosteroids within 4 weeks prior to Visit 1 or during the screening period
  • Treatment with intra-articular corticosteroids within 4 weeks prior to Visit 1 or during the screening period or anticipated need for intra-articular corticosteroids during the course of the study
  • Infection requiring hospital admission for >/=24 hours or requiring treatment with IV or IM antibiotics within 4 weeks prior to Visit 1 or during screening; Upper or lower respiratory tract infection within 4 weeks prior to Visit 1 or during screening; Active parasitic infection or Listeria monocytogenes infection within 6 months prior to Visit 1 or during screening
  • Active tuberculosis requiring treatment within 12 months prior to Visit 1
  • Known immunodeficiency, including, but not limited to, (HIV) infection
  • Evidence of acute or chronic hepatitis or known liver cirrhosis
  • History of interstitial lung disease, (COPD), or other lung disease other than asthma
  • Known current or current evaluation for potential malignancy
  • Current smoker or former smoker with a history of greater than (>) 10 pack-years
  • History of alcohol or drug abuse
  • Past and/or current use of any anti-interleukin (IL)-13 or anti-IL-4/IL-13 therapy, including lebrikizumab; use of other monoclonal antibody therapy, including omalizumab, within 6 months or 5 drug half-lives prior to Visit 1 (whichever is longer) or during screening
  • Initiation of or change in allergen immunotherapy within 3 months prior to Visit 1 or during screening
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,068 participants (actual)

Study arms

  • Experimental
    Lebrikizumab (125 mg)

    Participants will receive SC injection of lebrikizumab (125 mg) every 4 weeks for 104 weeks.

    Drug: Lebrikizumab

  • Experimental
    Lebrikizumab (37.5 mg)

    Participants will receive SC injection of lebrikizumab (37.5 mg) every 4 weeks for 104 weeks.

    Drug: Lebrikizumab

  • Placebo comparator
    Placebo

    Participants will receive SC injection of lebrikizumab matching placebo every 4 weeks for 52 weeks during placebo-controlled period and then SC injection of lebrikizumab at 125 or 37.5 mg for 52 weeks during active treatment extension period.

    Drug: Lebrikizumab · Drug: Placebo

Interventions

  • Lebrikizumab will be administered as SC injection at 125 or 37.5 mg every 4 weeks, for 104 weeks.

    Also known as: RO5490255

  • DrugPlacebo

    Lebrikizumab matching placebo will be administered as SC injection every 4 weeks for 52 weeks.

06

What researchers measure

Primary outcomes

  1. Rate of Asthma Exacerbations During the 52-Week Placebo-Controlled Period

    Time frame: Baseline up to Week 52

Secondary outcomes

  1. Absolute Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)

    Time frame: Baseline, Week 52

  2. Time to First Asthma Exacerbation

    Time frame: Baseline up to Week 52

  3. Change From Baseline in Standardized Asthma Quality of Life Questionnaire (AQLQ) Score

    Time frame: Baseline, Week 52

  4. Change from Baseline In Asthma Rescue Medication (Number of Puffs or Nebulized Treatments)

    Time frame: Baseline, Week 52

  5. Rate of Urgent Asthma-Related Urgent Health Care Utilization

    Time frame: Baseline up to Week 52

  6. Percentage of Participants With Adverse Events

    Time frame: Baseline up to Week 124

  7. Percentage of Participants With Anti-Therapeutic Antibodies to Lebrikizumab

    Time frame: Baseline up to Week 124 (assessed at Baseline, Weeks 4, 12, 24, 36, 52, 64, 76, 92, 104, 112, and 124)

  8. Change From Baseline in Asthma Control Questionnaire-5 (ACQ-5) Score

    Time frame: Baseline, Week 52

  9. Minimum Serum Concentration (Cmin) of Lebrikizumab

    Time frame: Predose (0 hour) on Weeks 4, 12, 24, 36, and 52

07

Study locations

232 sites
  • Clinical Research Center of Alabama, LLC
    Birmingham, Alabama 35209, United States
  • Medical Research of Arizona; Allergy, Asthma & Immu
    Scottsdale, Arizona 85251, United States
  • Quality of Life Medical & Research Center
    Tucson, Arizona 85712, United States
  • Kern Allergy Med Clinic, Inc.
    Bakersfield, California 93301, United States
  • Allergy and Asthma Relief Experts
    Granada Hills, California 91344, United States
  • Southern California Institute For Respiratory
    Los Angeles, California 90048, United States
  • Allergy & Asthma Consultants
    Redwood City, California 94063, United States
  • Integrated Research Group Inc
    Upland, California 91786, United States
  • Allergy & Asthma Medical Group; Clinical Research Division
    Walnut Creek, California 94598, United States
  • Asthma & Allergy; Associates, P.C.
    Colorado Springs, Colorado 80907, United States
  • Storms Clinical Research; Institute
    Colorado Springs, Colorado 80907, United States
  • National Jewish Health
    Denver, Colorado 80206, United States
  • Colorado Allergy & Asthma Centers, Pc
    Denver, Colorado 80230, United States
  • Western States Clinical Research, Inc
    Wheat Ridge, Colorado 80033, United States
  • Yale University School Of Medicine
    New Haven, Connecticut 06510, United States
  • Allergy Consultants PA
    Boca Raton, Florida 33431, United States
  • Research Institute of South Florida Inc
    Miami, Florida 33173, United States
  • Sarasota Clinical Research
    Sarasota, Florida 34239, United States
  • Georgia Pollens
    Albany, Georgia 31707, United States
  • Brookstone Clinical Res Ctr
    Columbus, Georgia 31904, United States
  • Southeast Regional Research Group
    Columbus, Georgia 31904, United States
  • DataQuest Medical Research
    Lawrenceville, Georgia 30045, United States
  • Aeroallergy Research Labs
    Savannah, Georgia 31406, United States
  • Atlanta Allergy & Asthma Clini
    Woodstock, Georgia 30188, United States
  • East-West Medical Research Institute
    Honolulu, Hawaii 96814, United States
  • Asthma & Allergy of Idaho
    Twin Falls, Idaho 83301, United States
  • The Allergy and Asthma Center
    Fort Wayne, Indiana 46804, United States
  • Cotton O'Neil Clinic; Stormont-Vail Hlth Care
    Topeka, Kansas 66606, United States
  • Dr. Paul Shapero
    Bangor, Maine 04401, United States
  • Asthma, Allergy & Sinus Center
    Baltimore, Maryland 21236, United States
  • Chesapeake Clinical Research
    Baltimore, Maryland 21236, United States
  • Howard County Center for Lung and Sleep, LLC
    Columbia, Maryland 21044, United States
  • Infinity Medical Research Inc
    North Dartmouth, Massachusetts 02747, United States
  • Clinical Research Inst
    Minneapolis, Minnesota 55402, United States
  • Asthma and Allergy Physicians LLC
    Brockton, Mississippi 02301, United States
  • Allergy Associates, Inc.
    Chesterfield, Missouri 63017, United States
  • Center For Pharmaceutical Research
    Kansas City, Missouri 64114, United States
  • Clinical Research Center, L.L.C.
    Saint Louis, Missouri 63141, United States
  • Clinical Research Consortium
    Las Vegas, Nevada 89119, United States
  • Adult Pediatric Allergy Central Jersey
    Edison, New Jersey 08820, United States
  • Patrick V. Perin, MD
    Teaneck, New Jersey 07666, United States
  • University of New Mexico; School of Med
    Albuquerque, New Mexico 87131, United States
  • Winthrop Univ Hospital
    Mineola, New York 11501, United States
  • Allergy Partners of Western NC
    Asheville, North Carolina 28801, United States
  • Allergy & Asthma Centre of Dayton
    Centerville, Ohio 45458, United States
  • Integrity People Services Research Company
    Oklahoma City, Oklahoma 73103, United States
  • Oklahoma Institute of Allergy and Asthma Clinical Research LLC
    Oklahoma City, Oklahoma 73131, United States
  • Vital Prospects Clin Res Pc
    Tulsa, Oklahoma 74136, United States
  • Penn State Milton S. Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • Allergy and Clinical Immunology Associates
    Pittsburgh, Pennsylvania 15241, United States
  • Asthma and Allergy Research Associates
    Upland, Pennsylvania 19013, United States
  • Neem Research Group, Inc.
    Columbia, South Carolina 29201, United States
  • Greenville Pharmaceutical Research
    Greenville, South Carolina 29615, United States
  • Upstate Pharmaceutical Research; Greenville
    Greenville, South Carolina 29615, United States
  • Future Search Clinical Trials L.P.
    Austin, Texas 78756, United States
  • Elliot J. Ginchansky, MD, PA
    Dallas, Texas 75230, United States
  • EPIMRD, Inc. DBA Western Sky Medical Research
    El Paso, Texas 79903, United States
  • Baylor College of Medicine; Dept of Medicine
    Houston, Texas 77030, United States
  • Allergy & Asthma Clin Cen TX
    Round Rock, Texas 78681, United States
  • Quality Assurance Research Ctr
    San Antonio, Texas 78205, United States
  • Discovery Clinical Trials
    San Antonio, Texas 78224, United States
  • Allergy & Asthma Research Center
    San Antonio, Texas 78229, United States
  • Live Oak Allergy & Asthma Clinic
    San Antonio, Texas 78233, United States
  • Allergy Associates of Utah
    Murray, Utah 84107, United States
  • Pulmonary Research of Albingdon
    Abingdon, Virginia 24210, United States
  • University of Wisconsin;Allergy & Asthma Clinical Research
    Madison, Wisconsin 53792, United States
  • Instituto de Investigaciones Clinicas-Mar del Plata
    Buenos Aires, B7600FZN, Argentina
  • Fundacion Cidea
    Buenos Aires, C1125 ABE, Argentina
  • Centro Respiratorio Infantil
    Rosario, 2000, Argentina
  • Centro Modelo de Cardiologia
    San Miguel de Tucuman, 4000, Argentina
  • CEMER Centro Médico de Enfermedades Respiratorias
    Vicente López, B1602DQD, Argentina
  • Concord Repatriation General Hospital; Department Thoracic Medicine
    Sydney, New South Wales 2139, Australia
  • AusTrials
    Brisbane, Queensland 4075, Australia
  • Princess Alexandra Hospital, Department of Respiratory and Sleep Medicine
    Brisbane, Queensland 4102, Australia
  • Respiratory Clinical Trials Pty Ltd
    Toorak Gardens, South Australia 5065, Australia
  • The Lung Institute of Western Australia; Sir Charles Gairdner Hospital
    Nedlands, Western Australia 6009, Australia
  • Private Practice
    Jambes, 5100, Belgium
  • UZ Leuven Gasthuisberg
    Leuven, 3000, Belgium
  • Specialized Hospital for Active Treatment for pneumo-phtysiatric diseases
    Ruse, 7002, Bulgaria
  • Multiprofile Hospital For Active Treatment - Dr. Bratan Shukerov AD
    Smolyan, 4700, Bulgaria
  • 5TH MHAT; Pulmonology
    Sofia, 1233, Bulgaria
  • National Multiprofile Hospital Tsar Boris III
    Sofia, 1233, Bulgaria
  • Medical Center for Specialized Outpatient Medical Care for Pulmonary Diseases
    Sofia, 1431, Bulgaria
  • SHATPD Sveta Sofia; Clin Pulmonary Diseases
    Sofia, 1431, Bulgaria
  • Alitera - Med - Medical Center EOOD
    Sofia, 1618, Bulgaria
  • Multiprofile Hospital For Active Treatment prof Kirkovich
    Stara Zagora, 6003, Bulgaria
  • Diagnostic and Consulting Centre Mladost - M OOD
    Varna, 9020, Bulgaria
  • Medical Center Tara OOD
    Veliko Tarnovo, 5000, Bulgaria
  • Cheema Research, Inc
    Mississauga, Ontario L5A 3V4, Canada
  • Ottawa Allergy Research Corp
    Ottawa, Ontario K1Y 4G2, Canada
  • Manna Research
    Toronto, Ontario M9W 4L6, Canada
  • Dr Anil Dhar Professional Medicine Corporation
    Windsor, Ontario N8X-5A6, Canada
  • Del Carpio Jaime Dr - Allergiste & Immunologue
    Montreal, Quebec H3H 1T8, Canada
  • Fakultni nemocnice Hradec Kralove
    Hradec Kralove, 500 05, Czechia
  • Thomayerova nemocnice
    Praha 4 - Krc, 140 59, Czechia
  • Ordinace pro tuberkulozu a respiracni nemoci
    Strakonice, 38601, Czechia
  • KASMED, s.r.o.; Alergologie a klinicka imunologie
    Tabor, 390 01, Czechia
  • Centre Hospitalier Universitaire de Bicêtre
    Le Kremlin-bicêtre, 94275, France
  • Hôpital de La Croix Rousse
    Lyon, 69004, France
  • Groupe Hospitalier Cochin St Vincent de Paul La Roche Guyon
    Paris, 75014, France

Showing the first 100 of 232 sites across 26 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Chen M, Shepard K 2nd, Yang M, Raut P, Pazwash H, Holweg CTJ, Choo E. Overlap of allergic, eosinophilic and type 2 inflammatory subtypes in moderate-to-severe asthma. Clin Exp Allergy. 2021 Apr;51(4):546-555. doi: 10.1111/cea.13790. Epub 2021 Jan 7. PubMed 33217063 ↗
  • N Bauer R, Yang X, L Staton T, Olsson J, Holweg CTJ, R Arron J, Matthews JG, Choy DF. Seasonal variability of lung function and Asthma Quality of Life Questionnaire Scores in adults with uncontrolled asthma. BMJ Open Respir Res. 2019 Nov 11;6(1):e000406. doi: 10.1136/bmjresp-2019-000406. eCollection 2019. PubMed 31803473 ↗
  • Hanania NA, Korenblat P, Chapman KR, Bateman ED, Kopecky P, Paggiaro P, Yokoyama A, Olsson J, Gray S, Holweg CT, Eisner M, Asare C, Fischer SK, Peng K, Putnam WS, Matthews JG. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2016 Oct;4(10):781-796. doi: 10.1016/S2213-2600(16)30265-X. Epub 2016 Sep 5. PubMed 27616196 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2013 to primary completion in Jan 2017, 41 months.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 41 months is above that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2013
First posted
Jun 4, 2013
StartActual
Jul 31, 2013
Primary completionActual
Jan 2, 2017
CompletionActual
Jan 2, 2017
Last update
May 19, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01868061
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 4, 2013
Start date
Jul 31, 2013
Primary completion
Jan 2, 2017
Completion
Jan 2, 2017
Last update
May 19, 2017

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lebrikizumab

Start the discussion